Accelerated Pharma (Accelerated Pharma) FCF Yield % : 0.00 (As of May. 21, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Accelerated Pharma's Trailing 12-Month Free Cash Flow is $0.00 Mil, and Market Cap is $0.00 Mil. Therefore, Accelerated Pharma's FCF Yield % for today is 0.00%.

The historical rank and industry rank for Accelerated Pharma's FCF Yield % or its related term are showing as below:

ACCP's FCF Yield % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: -0.48
* Ranked among companies with meaningful FCF Yield % only.

Accelerated Pharma's FCF Margin % for the quarter that ended in Mar. 2017 was 0.00%.

Accelerated Pharma FCF Yield % Historical Data

The historical data trend for Accelerated Pharma's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma FCF Yield % Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

FCF Yield %

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
FCF Yield %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Accelerated Pharma's FCF Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerated Pharma's FCF Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's FCF Yield % falls into.

Accelerated Pharma FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Accelerated Pharma's FCF Yield % for the fiscal year that ended in Dec. 2016 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-1.921	/	0
	=	N/A%

Accelerated Pharma's annualized FCF Yield % for the quarter that ended in Mar. 2017 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-0.24	*	4	/	0
	=	N/A%

Accelerated Pharma FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Accelerated Pharma FCF Yield % Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines